Equity
€195,050 ▲ 69.8%
Equity rose in 2025 from €114,838 to €195,050.
D-PHARMA
Lifetime
3 annual accounts with figures on one time axispeak €113,258 (2024)
€111,763▼ 1.3%
peak €85,743 (2024)
€80,212▼ 6.4%
peak €195,050 (2025)
€195,050▲ 69.8%
€31,413▼ 10.7%
Board1 name since 2023
1 director
Documentsfilings and deeds
29-01-202691 days before the deadline
2025micro format
Equity from €114,838 to €195,050Investments €3,132Cash from €86,321 to €128,032
Key points
from the 2025 annual accountsTurnover
≈ €340,000 estimated
The micro format states no turnover.
Investments
€3,132 4.6 × depreciation
Green is investment, beige is depreciation.
Liquidity
7.10 was 4.62 in 2024
Short-term debts fell from €32,246 to €31,413.
Starting capital
€2,500 1,000 shares
Position in the sector
€80,212
Higher net result than 94% of companies in retail trade. Sector median €4,763 · 25,208 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 39,274 companies had the same profile as D-PHARMA has now. Each dot stands for 99 companies, two years later.
95.8%
were still trading
2.3%
stopped another way
1.8%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 39,274 companies, not a prediction for D-PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director
- 999 sharesdeed of 11-08-2023
- 1 sharedeed of 11-08-2023
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0804682997
Incorporation
Founding capital of €2,500, 1,000 shares · Founders: and · Appointment: (director) · published on 11-08-2023 · Gazette deed
First establishment
Meeslaan 14, Brasschaat
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| D-PHARMA Brasschaat | €226,463 | €111,763 | 86.1% | - |
| YASMIN LIBBRECHT Antwerp | €258,250 | €93,300 | 81.2% | - |
| LIWOMA Kontich | €289,010 | €110,490 | 74.9% | - |
| Rougeardent SRL Liège | €242,680 | €125,459 | 68.3% | - |
| RS PHARMA Berchem-Sainte-Agathe | €201,141 | €121,827 | 14.0% | - |
| PHARMASOLUTIONS Linkebeek | €215,437 | €98,035 | 84.1% | - |
| NZOSSHEALTH Woluwe-Saint-Lambert | €201,994 | €89,808 | 91.5% | - |
These companies have the same main activity as D-PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €201,000 and €289,000, founded in 2023.
Official details
Source: KBO- Status
- Active since 09-08-2023Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730and 1 other
- Establishment unit
- 2.348.067.9142930 Brasschaat, since 09-08-2023
- Financial year end
- 30 September
- Peppol
- Reachable since 05-01-2026
Annual accounts to 30-09-2025
- €226,463▲ 51.0%
- Filing
- Filed on 29-01-2026, 91 days before the end of the filing period
Insights on D-PHARMA
D-PHARMA files the micro format. That format states no turnover. The gross margin rose from €33,429 in 2023 to €111,763 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about D-PHARMA
- What is the company number of D-PHARMA?
- The company number of D-PHARMA is 0804.682.997. The VAT number is the same number with BE in front: BE 0804.682.997.
- Where is D-PHARMA based?
- The registered office is at Meeslaan 14, 2930 Brasschaat.Company details
- What does D-PHARMA do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of D-PHARMA?
- D-PHARMA is a private limited company (BV).
- When was D-PHARMA founded?
- D-PHARMA was founded on 09-08-2023.
- Is D-PHARMA still active?
- Yes, D-PHARMA is an active enterprise in the KBO register.
- What is the turnover of D-PHARMA?
- The turnover in financial year 2025 is ≈ €340,000. This figure is estimated from the gross margin of €111,763 and 31 comparable companies (NACE 477). It probably lies between €240,000 and €640,000.Financials
- Is D-PHARMA profitable?
- In financial year 2025, D-PHARMA made a profit of €80,212.
- Where can I find the annual accounts of D-PHARMA?
- D-PHARMA filed 3 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of D-PHARMA due?
- D-PHARMA must file the annual accounts for financial year 2026 by 30-04-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.